Animal and human studies have indicated that viloxazine hydrochloride, an antidepressant drug with a half-life of 3-4 h in most subjects at low dosage, is rapidly and almost completely absorbed after oral administration. A sustained-release form might be useful to decrease the frequency of administration. In our study, the pharmacokinetics of sustained-release form containing 300 mg viloxazine were compared with 300 mg conventional viloxazine in 11 normal volunteers (6 women, 5 men). Wide interindividual variations were observed with respect to plasma levels, but there was no significant statistical correlation between weight and blood concentration (conventional form: Cmax = 3,599 +/- 579 ng/ml, tmax = 86 +/- 26 min; sustained-release form: Cmax = 1,917 +/- 922 ng/ml, tmax = 215 +/- 77 min). Twelve hours after administration, plasma levels ranged between 540 and 1,600 ng/ml for the conventional form and between 660 and 2,120 ng/ml for the sustained-release form. Despite the great interindividual variation this new viloxazine form appears to be of interest for one daily administration.
No takes yet. Share an insight, caveat, or question.
Kergueris et al. (2008) studied this question.